Novartis Pharma AG: Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya (fingolimod) dosing regimen patent
Ad hoc announcement pursuant to Art. 53 LR Basel, June 21, 2021 - Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a new, negative decision regarding t…
Novartis Pharma AG: Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya (fingolimod) dosing regimen patent
Ad hoc announcement pursuant to Art. 53 LR Basel, June 21, 2021 - Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a new, negative decision regarding t…